The Department for Health and Social Care has asked us to carry out a Single Technology Appraisal of galcanezumab for preventing migraine.
The appraisal is expected to start in approximately late November 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE until after the anticipated marketing authorisation has been received, in order to facilitate a suitably comprehensive and robust evidence submission.